+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Gastroenterology - Global Strategic Business Report

  • PDF Icon

    Report

  • 401 Pages
  • May 2025
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6087861
The global market for Gastroenterology was valued at US$34.1 Billion in 2024 and is projected to reach US$45.7 Billion by 2030, growing at a CAGR of 5.0% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Gastroenterology market.

Global Gastroenterology Market - Key Trends & Drivers Summarized

Why Is Gastroenterology Becoming a Key Focus in Modern Medicine?

Gastroenterology, the branch of medicine focused on the digestive system and its disorders, has become an increasingly critical field in modern healthcare due to the rising prevalence of digestive diseases globally. The growing incidence of conditions such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), inflammatory bowel diseases (IBD) like Crohn’s disease and ulcerative colitis, and liver diseases like non-alcoholic fatty liver disease (NAFLD) is propelling the demand for specialized care in gastroenterology. Factors such as aging populations, changes in dietary habits, increased awareness of digestive health, and the global rise in conditions like obesity and diabetes contribute to the growing burden of gastrointestinal disorders. Additionally, environmental and genetic factors are increasingly being recognized as major contributors to gastrointestinal diseases, making gastroenterology more relevant in understanding both the etiology and treatment of these conditions. As a result, gastroenterology has become an essential part of preventive healthcare, with early diagnosis and management being crucial for improving patient outcomes. Advances in diagnostics, treatments, and a growing emphasis on personalized medicine are making gastroenterology an exciting and rapidly evolving area of modern healthcare, with an increasing number of healthcare providers and researchers focusing on this field to address the growing global health challenge.

How Are Technological Advancements Transforming Gastroenterology Practices?

Technological advancements have dramatically transformed the field of gastroenterology, significantly improving both diagnostic accuracy and treatment effectiveness. In diagnostic imaging, the development of high-definition endoscopy, capsule endoscopy, and confocal laser endomicroscopy (CLE) has enhanced the ability to detect gastrointestinal abnormalities at earlier stages. For instance, capsule endoscopy allows for the non-invasive visualization of the entire gastrointestinal tract, particularly the small intestine, a traditionally difficult area to assess. Additionally, advancements in biomarkers and molecular testing are allowing for more accurate diagnosis and personalized treatment plans, particularly in the case of colorectal cancer, where genetic testing can help identify risk factors and tailor therapies. Artificial intelligence (AI) is also playing a growing role in gastroenterology, particularly in the analysis of endoscopic images and patient data to identify patterns that may be difficult for human practitioners to detect. AI algorithms can assist in early detection of gastrointestinal cancers, inflammatory diseases, and other conditions by identifying subtle changes in imaging and laboratory results. Furthermore, the use of minimally invasive techniques, such as endoscopic ultrasound (EUS) and endoscopic retrograde cholangiopancreatography (ERCP), has significantly reduced patient recovery time and risk of complications compared to traditional surgical methods. These technological innovations are improving patient outcomes, enhancing treatment precision, and enabling earlier detection and more effective management of gastrointestinal disorders.

What Are the Key Factors Driving Growth in the Gastroenterology Market?

The gastroenterology market is experiencing significant growth due to several driving factors, including an aging population, lifestyle changes, and increasing awareness of gastrointestinal health. As the global population ages, there is a higher incidence of gastrointestinal diseases such as colorectal cancer, liver diseases, and functional gastrointestinal disorders, which are more common in older adults. Additionally, lifestyle factors such as poor diet, lack of exercise, and high stress levels have contributed to an increase in conditions like obesity, GERD, and IBD. The rising prevalence of obesity, which is closely linked to conditions like NAFLD and gastroesophageal reflux disease, is becoming a global health crisis, particularly in developed countries. As awareness of the connection between lifestyle and gastrointestinal health grows, more people are seeking preventive care, regular screenings, and treatments for digestive disorders. The rise in global awareness of conditions like colorectal cancer and hepatitis C has also contributed to the increasing demand for gastroenterology services. The development of screening programs, particularly for colorectal cancer, has led to higher detection rates and better outcomes, further driving the growth of the gastroenterology market. Additionally, increasing access to healthcare in emerging economies is expanding the reach of gastroenterology services, where rising middle-class populations are demanding better care for digestive disorders. The expansion of specialized gastroenterology centers and the growing availability of advanced diagnostics and treatments are helping to address the growing global burden of digestive diseases.

What Are the Primary Drivers Behind the Growth of the Gastroenterology Market?

The growth of the gastroenterology market is driven by several factors that combine advancements in technology, increasing disease prevalence, and a focus on patient-centered care. A key driver is the rising global prevalence of gastrointestinal diseases, particularly conditions like IBD, colorectal cancer, and NAFLD, which are more common due to modern lifestyle factors such as poor diets, smoking, and sedentary lifestyles. As these diseases become more prevalent, there is a greater demand for gastroenterology specialists, diagnostics, and treatments to manage these conditions. Additionally, technological innovations in diagnostics and treatments, such as AI-assisted endoscopy and minimally invasive surgeries, are improving the accuracy, speed, and patient outcomes associated with gastroenterology procedures. The integration of genomics into gastroenterology is also driving growth, as the field moves toward personalized medicine and targeted therapies for gastrointestinal diseases. The increasing focus on preventive care is another significant growth driver. With improved access to screenings for colorectal cancer, hepatitis, and other gastrointestinal diseases, healthcare systems can catch these conditions at earlier stages, leading to more effective treatment and improved survival rates. Moreover, the expanding middle class in emerging markets is contributing to the global growth of gastroenterology services, as more people seek specialized care for digestive disorders. Public health campaigns, government initiatives, and international efforts to raise awareness of gastrointestinal diseases are further fueling the demand for gastroenterology services. Finally, the growing interest in gut microbiota and its role in gastrointestinal health and overall well-being is sparking new research and treatment options, positioning gastroenterology at the forefront of medical innovation. Together, these factors are driving the expansion of the gastroenterology market and enhancing the quality of care for patients with digestive diseases worldwide.

Report Scope

The report analyzes the Gastroenterology market, presented in terms of market value (US$ Thousand). The analysis covers the key segments and geographic regions outlined below.

Segments: Drug Type (Biologics / Biosimilars, Antacids, Laxatives, Antidiarrheal Agents, Antiemetics, Antiulcer Agents, Other Drug Types); Disease Type (Inflammatory Bowel Diseases, Crohn's Disease, Ulcerative Colitis, Irritable Bowel Syndrome, Gastroesophageal Reflux Disease, Liver Diseases, Colorectal Cancer, Other Disease Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies).

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Biologics / Biosimilars segment, which is expected to reach US$11.3 Billion by 2030 with a CAGR of a 3.8%. The Antacids segment is also set to grow at 4.8% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, valued at $9.3 Billion in 2024, and China, forecasted to grow at an impressive 7.7% CAGR to reach $8.9 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Gastroenterology Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Gastroenterology Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Gastroenterology Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of players such as AbbVie Inc., Abbott Laboratories, AstraZeneca plc, Bayer AG, Bausch Health Companies Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 41 companies featured in this Gastroenterology market report include:

  • AbbVie Inc.
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Ferring Pharmaceuticals
  • GI Alliance
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Medtronic plc
  • Novartis AG
  • Olympus Corporation
  • Pfizer Inc.
  • Salix Pharmaceuticals
  • Sanofi S.A.
  • Sebela Pharmaceuticals
  • Takeda Pharmaceutical Company

Tariff Impact Analysis: Key Insights for 2025

Global tariff negotiations across 180+ countries are reshaping supply chains, costs, and competitiveness. This report reflects the latest developments as of April 2025 and incorporates forward-looking insights into the market outlook.

The analysts continuously track trade developments worldwide, drawing insights from leading global economists and over 200 industry and policy institutions, including think tanks, trade organizations, and national economic advisory bodies. This intelligence is integrated into forecasting models to provide timely, data-driven analysis of emerging risks and opportunities.

What's Included in This Edition:

  • Tariff-adjusted market forecasts by region and segment
  • Analysis of cost and supply chain implications by sourcing and trade exposure
  • Strategic insights into geographic shifts

Buyers receive a free July 2025 update with:

  • Finalized tariff impacts and new trade agreement effects
  • Updated projections reflecting global sourcing and cost shifts
  • Expanded country-specific coverage across the industry

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of COVID-19 and a Looming Global Recession
  • Gastroenterology - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Increasing Prevalence of Gastrointestinal Disorders Drives Demand for Gastroenterology Services and Treatments
  • Here`s the Story: How Advancements in Endoscopic Technology Are Revolutionizing Gastroenterology Diagnostics
  • Rising Awareness of Digestive Health and Wellness Fuels Growth in Preventive and Diagnostic Gastroenterology Services
  • Technological Innovations in Minimally Invasive Procedures Expand Treatment Options for Gastrointestinal Disorders
  • Surge in Aging Populations Globally Increases the Need for Gastroenterology Care and Disease Management
  • Here`s How the Growing Focus on Personalized Medicine is Shaping the Future of Gastroenterology Treatments
  • Rising Incidence of Inflammatory Bowel Diseases (IBD) and Celiac Disease Strengthens the Business Case for Specialized Care
  • Expanding Role of Telemedicine and Remote Monitoring Drives Access to Gastroenterology Services in Underserved Areas
  • Increasing Research and Clinical Trials in Microbiome and Gut Health Create New Opportunities for Therapeutic Advancements
  • Here`s How Advances in Artificial Intelligence and Machine Learning are Revolutionizing Gastroenterology Diagnostics
  • Growing Demand for Targeted Therapies and Biologics in Treating Gastrointestinal Disorders Expands Treatment Options
  • Global Increase in Obesity and Lifestyle-Related Disorders Drives Growth in Gastroenterology-Based Disease Prevention
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Gastroenterology Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 3: World Historic Review for Gastroenterology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 4: World 15-Year Perspective for Gastroenterology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Biologics / Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 6: World Historic Review for Biologics / Biosimilars by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 7: World 15-Year Perspective for Biologics / Biosimilars by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 9: World Historic Review for Antacids by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 10: World 15-Year Perspective for Antacids by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 12: World Historic Review for Laxatives by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 13: World 15-Year Perspective for Laxatives by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 14: World Recent Past, Current & Future Analysis for Antidiarrheal Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 15: World Historic Review for Antidiarrheal Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 16: World 15-Year Perspective for Antidiarrheal Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 17: World Recent Past, Current & Future Analysis for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 18: World Historic Review for Antiemetics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 19: World 15-Year Perspective for Antiemetics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 20: World Recent Past, Current & Future Analysis for Antiulcer Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 21: World Historic Review for Antiulcer Agents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 22: World 15-Year Perspective for Antiulcer Agents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 23: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 24: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 25: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 26: World Recent Past, Current & Future Analysis for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 27: World Historic Review for Ulcerative Colitis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 28: World 15-Year Perspective for Ulcerative Colitis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 29: World Recent Past, Current & Future Analysis for Irritable Bowel Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 30: World Historic Review for Irritable Bowel Syndrome by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 31: World 15-Year Perspective for Irritable Bowel Syndrome by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 32: World Recent Past, Current & Future Analysis for Gastroesophageal Reflux Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 33: World Historic Review for Gastroesophageal Reflux Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 34: World 15-Year Perspective for Gastroesophageal Reflux Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 35: World Recent Past, Current & Future Analysis for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 36: World Historic Review for Liver Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 37: World 15-Year Perspective for Liver Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 38: World Recent Past, Current & Future Analysis for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 39: World Historic Review for Colorectal Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 40: World 15-Year Perspective for Colorectal Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 41: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 42: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 43: World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 44: World Recent Past, Current & Future Analysis for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 45: World Historic Review for Inflammatory Bowel Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 46: World 15-Year Perspective for Inflammatory Bowel Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 47: World Recent Past, Current & Future Analysis for Crohn`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 48: World Historic Review for Crohn`s Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 49: World 15-Year Perspective for Crohn`s Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 50: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 51: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 52: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 53: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 54: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 55: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • Table 56: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • Table 57: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • Table 58: World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
CANADA
JAPAN
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
CHINA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
EUROPE
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
FRANCE
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
GERMANY
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
ITALY
UNITED KINGDOM
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
SPAINRUSSIAREST OF EUROPE
ASIA-PACIFIC
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
AUSTRALIA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
INDIA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Gastroenterology Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • AbbVie Inc.
  • Abbott Laboratories
  • AstraZeneca plc
  • Bayer AG
  • Bausch Health Companies Inc.
  • Boehringer Ingelheim GmbH
  • Boston Scientific Corporation
  • Cipla Ltd.
  • Ferring Pharmaceuticals
  • GI Alliance
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Medtronic plc
  • Novartis AG
  • Olympus Corporation
  • Pfizer Inc.
  • Salix Pharmaceuticals
  • Sanofi S.A.
  • Sebela Pharmaceuticals
  • Takeda Pharmaceutical Company

Table Information